Optimizing the dose of upifitamab rilsodotin (UpRi; XMT-1536), a NaPi2b-directed dolaflexin antibody drug conjugate (ADC): A posthoc analysis of a phase 1b expansion study in ovarian cancer (319)

Objectives: Effective and well-tolerated treatments for platinum- resistant ovarian cancer (PROC) remain a substantial unmet medical need. UpRi is a first-in-class Dolaflexin ADC targeting NaPi2b, a sodium-dependent phosphate transporter broadly expressed in high-grade serous epithelial ovarian canc...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Gynecologic oncology Jg. 166; S. S166
Hauptverfasser:	Monk, Bradley, Concin, Nicole, Richardson, Debra, Ray-Coquard, Isabelle, Pothuri, Bhavana, Marth, Christian, Bernardo, Patricia, Burger, Robert, Im, Ellie, Aldairy, Wassim, Coleman, Robert, Mirza, Mansoor
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	Elsevier Inc 01.08.2022
Schlagworte:	Hematology, Oncology, and Palliative Medicine Obstetrics and Gynecology
ISSN:	0090-8258
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!